AREG and cancer: In this study, we uncovered that AREG, a soluble factor produced by the treatment‐damaged TME, confers pronounced resistance on surviving cancer cells and simultaneously creates an immunosuppressive microenvironment by engaging PD‐L1, a type I transmembrane protein that functionally activates the immune checkpoint (Figure 7h).